Multiple sclerosis (MS) is an autoimmune disease resulting in damage to the insulating covers of nerve cells in the brain and spinal cord.[3] As a demyelinating disease, MS disrupts the nervous system's ability to transmit signals, resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems.[1][8][9] Symptoms include double vision, vision loss, eye pain, muscle weakness, and loss of sensation or coordination.[3][10][11] MS takes several forms, with new symptoms either occurring in isolated attacks (relapsing forms) or building up over time (progressive forms).[12][13] In relapsing forms of MS symptoms may disappear completely between attacks, although some permanent neurological problems often remain, especially as the disease advances.[13] In progressive forms of MS, bodily function slowly deteriorates once symptoms manifest and will steadily worsen if left untreated.[14]
While its cause is unclear, the underlying mechanism is thought to be due to either destruction by the immune system or inactivation of myelin-producing cells.[4] Proposed causes for this include immune dysregulation, genetics, and environmental factors, such as viral infections.[15][16][8][17] The McDonald criteria are a frequently updated set of guidelines used to establish an MS diagnosis.[18]
There is no cure for MS.[19] Current treatments aim to mitigate inflammation and resulting symptoms from acute flares and prevent further attacks with disease-modifying medications.[8][20]Physical therapy[7] and occupational therapy,[21] along with patient-centered symptom management, can help with people's ability to function. The long-term outcome is difficult to predict; better outcomes are more often seen in women, those who develop the disease early in life, those with a relapsing course, and those who initially experienced few attacks.[22]
MS is the most common immune-mediated disorder affecting the central nervous system (CNS).[23] Nearly one million people in the United States had MS in 2022,[24] and in 2020, about 2.8 million people were affected globally, with rates varying widely in different regions and among different populations.[25] The disease usually begins between the ages of 20 and 50 and is twice as common in women as in men.[2] MS was first described in 1868 by French neurologist Jean-Martin Charcot.[26]
The name "multiple sclerosis" is short for multiple cerebro-spinal sclerosis, which refers to the numerous glial scars (or sclerae – essentially plaques or lesions) that develop on the white matter of the brain and spinal cord.[26]
As MS lesions can affect any part of the CNS, a person with MS can have almost any neurological symptom or sign referable to it.
Fatigue is one of the most common symptoms of MS.[27][28] Roughly 65% of people with MS experience fatigue symptomatology, and of these, some 15–40% report fatigue as their most disabling MS symptom.[29]
Autonomic, visual, motor, and sensory problems are also among the most common symptoms.[1]
The specific symptoms depend on the locations of the lesions within the nervous system, and may include focal loss of sensitivity or changes in sensation in the limbs, such as feeling tingling, pins and needles, or numbness; limb motor weakness/pain, blurred vision,[30]pronounced reflexes, muscle spasms, difficulty with ambulation (walking), difficulties with coordination and balance (ataxia); problems with speech[31] or swallowing, visual problems (optic neuritis manifesting as eye pain & vision loss,[32] or nystagmus manifesting as double vision), fatigue, and bladder and bowel difficulties (such as urinary or fecal incontinence or retention), among others.[1] When MS is more advanced, walking difficulties lead to a higher risk of falling.[33][20][34]
Difficulties in thinking and emotional problems such as depression or unstable mood are also common.[1][35] The primary deficit in cognitive function that people with MS experience is slowed information-processing speed, with memory also commonly affected, and executive function less commonly. Intelligence, language, and semantic memory are usually preserved, and the level of cognitive impairment varies considerably between people with MS.[36][37][38]
Uhthoff's phenomenon, a worsening of symptoms due to exposure to higher-than-usual temperatures, and Lhermitte's sign, an electrical sensation that runs down the back when bending the neck, are particularly characteristic of MS, although may not always be present.[1] Another presenting manifestation that is rare but highly suggestive of a demyelinating process such as MS is bilateral internuclear ophthalmoplegia, where the patient experiences double vision when attempting to move their gaze to the right & left.[39]
Some 60% or more of MS patients find their symptoms, particularly including fatigue,[40] are affected by changes in body temperature.[41][42][43]
Measures of disability
The main measure of disability and severity is the expanded disability status scale (EDSS), with other measures such as the multiple sclerosis functional composite being increasingly used in research.[44][45][46] EDSS is also correlated with falls in people with MS.[10] While it is a popular measure, EDSS has been criticized for some of its limitations, such as overreliance on walking.[47][10]
Disease course
Prodromal phase
MS may have a prodromal phase in the years leading up to its manifestation, characterized by psychiatric issues, cognitive impairment, and increased use of healthcare.[48][49]
Onset
85% of cases begin as a clinically isolated syndrome (CIS) over a number of days with 45% having motor or sensory problems, 20% having optic neuritis,[32] and 10% having symptoms related to brainstem dysfunction, while the remaining 25% have more than one of the aforementioned difficulties.[5] With optic neuritis as the most common presenting symptom, people with MS notice sub-acute loss of vision, often associated with pain worsening on eye movement, and reduced color vision. Early diagnosis of MS-associated optic neuritis helps timely initiation of targeted treatments. However, it is crucial to adhere to established diagnostic criteria when treating optic neuritis due to the broad range of alternative causes, such as neuromyelitis optica spectrum disorder (NMOSD), and other autoimmune or infectious conditions. The course of symptoms occurs in two main patterns initially: either as episodes of sudden worsening that last a few days to months (called relapses, exacerbations, bouts, attacks, or flare-ups) followed by improvement (85% of cases) or as a gradual worsening over time without periods of recovery (10–15% of cases).[2] A combination of these two patterns may also occur[13] or people may start in a relapsing and remitting course that then becomes progressive later on.[2]
Relapses
Relapses are usually unpredictable, occurring without warning.[1] Exacerbations rarely occur more frequently than twice per year.[1] Some relapses, however, are preceded by common triggers and they occur more frequently during spring and summer.[50] Similarly, viral infections such as the common cold, influenza, or gastroenteritis increase their risk.[1]Stress may also trigger an attack.[51]
Many people with MS who become pregnant experience lower symptoms[55][56][57] During the first months after delivery, the risk increases.[1] Overall, pregnancy does not seem to influence long-term disability.[1]
Causes
MS is an autoimmune disease with a combination of genetic and environmental causes underlying it. Both T-cells and B-cells are involved, although T-cells are often considered to be the driving force of the disease. The causes of the disease are not fully understood. The Epstein-Barr Virus (EBV) has been shown to be directly present in the brain of most cases of MS and the virus is transcriptionally active in infected cells.[58][59] EBV nuclear antigens are believed to be involved in the pathogenesis of multiple sclerosis, but not all people with MS have signs of EBV infection.[15] Dozens of human peptides have been identified in different cases of the disease, and while some have plausible links to infectious organisms or known environmental factors, others do not.[60]
Immune dysregulation
Failure of both central and peripheral nervous system clearance of autoreactive immune cells is implicated in MS development.[15] The thymus is responsible for the immune system's central tolerance, where autoreactive T-cells are killed without being released into circulation. A similar mechanism kills autoreactive B-cells in the bone marrow. Some autoreactive T-cells & B-cells may escape these defense mechanisms, which is where peripheral immune tolerance defenses take action by preventing them from causing disease. However, these additional lines of defense can still fail.[15][20] Further detail on immune dysregulation's contribution to MS risk is provided in the pathophysiology section of this article as well as the standalone article on the pathophysiology of MS.
Infectious agents
Early evidence suggested the association between several viruses with human demyelinating encephalomyelitis, and the occurrence of demyelination in animals caused by some viral infections.[61] One such virus, Epstein-Barrvirus (EBV), can cause infectious mononucleosis and infects about 95% of adults, though only a small proportion of those infected later develop MS.[62][16][63][59] A study of more than 10 million US military members compared 801 people who developed MS to 1,566 matched controls who did not. The study found a 32-fold increased risk of MS development following EBV infection. It did not find an increased risk after infection with other viruses, including the similar cytomegalovirus. These findings strongly suggest that EBV plays a role in MS onset, although EBV alone may be insufficient to cause it.[16][63]
The nuclear antigen of EBV, which is the most consistent marker of EBV infection across all strains,[64] has been identified as a direct source of autoreactivity in the human body. These antigens appear more likely to promote autoimmunity vitamin D-deficient persons. The exact nature of this relationship is poorly understood.[65][15]
Genetics
HLA region of chromosome6: Changes in this area increase the probability of getting MS.
MS is not considered a hereditary disease, but several genetic variations have been shown to increase its risk.[66] Some of these genes appear to have higher expression levels in microglial cells than expected by chance.[67] The probability of developing MS is higher in relatives of an affected person, with a greater risk among those more closely related.[8] An identical twin of an affected individual has a 30% chance of developing MS, 5% for a nonidentical twin, 2.5% for a sibling, and an even lower chance for a half-sibling.[1][8][68] If both parents are affected, the risk in their children is 10 times that of the general population.[2] MS is also more common in some ethnic groups than others.[69]
The prevalence of MS from a geographic standpoint resembles a gradient, with it being more common in people who live farther from the equator (e.g. those who live in northern regions of the world), although exceptions exist. The cause of this geographical pattern is not clear, although exposure to ultraviolet B (UVB) radiation and vitamin D levels may be possible explanations.[72][15] For example, those who live in northern regions of the world have less exposure to UVB radiation and subsequently lower levels of vitamin D, which is a known risk factor for developing MS.[15] Inversely, those who live in areas of relatively higher sun exposure and subsequently increased UVB radiation have a decreased risk of developing MS.[15] As of 2019, the north–south gradient of incidence is still present and is increasing.[73]
On the other hand, MS is more common in regions with northern European populations,[1] so the geographic variation may simply reflect the global distribution of these high-risk populations.[2]
A relationship between season of birth and MS lends support to this idea, with fewer people born in the Northern Hemisphere in November compared to May being affected later in life.[74]
Environmental factors may play a role during childhood, with several studies finding that people who move to a different region of the world before the age of 15 acquire the new region's risk of MS. If migration takes place after age 15, the persons retain the risk of their home country.[1][75] Some evidence indicates that the effect of moving may still apply to people older than 15.[1]
There are some exceptions to the above-mentioned geographic pattern. These include ethnic groups that are at low risk and that live far from the equator such as the Sami, Amerindians, Canadian Hutterites, New Zealand Māori,[76] and Canada's Inuit,[72] as well as groups that have a relatively high risk and that live closer to the equator such as Sardinians,[72] inland Sicilians,[77]Palestinians, and Parsi.[76]
Smoking may be an independent risk factor for MS.[85]Stress may also be a risk factor, although the evidence to support this is weak.[75] Association with occupational exposures and toxins—mainly organic solvents[86]—has been evaluated, but no clear conclusions have been reached.[75]Vaccinations were studied as causal factors; most studies, though, show no association.[75][87] Several other possible risk factors, such as diet and hormone intake, have been evaluated, but evidence on their relation with the disease is "sparse and unpersuasive".[85]Gout occurs less than would be expected and lower levels of uric acid have been found in people with MS. This has led to the theory that uric acid is protective, although its exact importance remains unknown.[88] Obesity during adolescence and young adulthood is a risk factor for MS.[89]
Multiple sclerosis is an autoimmune disease, primarily mediated by T-cells.[15] The three main characteristics of MS are the formation of lesions in the central nervous system (also called plaques), inflammation, and the destruction of myelin sheaths of neurons. These features interact in a complex and not yet fully understood manner to produce the breakdown of nerve tissue, and in turn, the signs and symptoms of the disease.[1] Damage is believed to be caused, at least in part, by attack on the nervous system by a person's own immune system.[1]
Immune dysregulation
As briefly detailed in the causes section of this article, MS is currently thought to stem from a failure of the body's immune system to kill off autoreactive T-cells & B-cells.[15] Currently, the T-cell subpopulations that are thought to drive the development of MS are autoreactive CD8+ T-cells, CD4+ helper T-cells, and TH17 cells. These autoreactive T-cells produce substances called cytokines that induce an inflammatory immune response in the CNS, leading to the development of the disease.[15] More recently, however, the role of autoreactive B-cells has been elucidated. Evidence of their contribution to the development of MS is implicated through the presence of oligoclonal IgG bands (antibodies produced by B-cells) in the CSF of patients with MS.[15][20] The presence of these oligoclonal bands has been used as supportive evidence in clinching a diagnosis of MS.[90] As similarly described before, B-cells can also produce cytokines that induce an inflammatory immune response via activation of autoreactive T-cells.[15][91] As such, higher levels of these autoreactive B-cells are associated with an increased number of lesions & neurodegeneration as well as worse disability.[15]
Another cell population that is becoming increasingly implicated in MS is microglia. These cells are resident to & keep watch over the CNS, responding to pathogens by shifting between pro- & anti-inflammatory states. Microglia are involved in the formation of MS lesions and be involved in other diseases that primarily affect the CNS white matter. However, because of their ability to switch between pro- & anti-inflammatory states, microglia have also been shown to be able to assist in remyelination & subsequent neuron repair.[15] As such, microglia are thought to be participating in both acute & chronic MS lesions, with 40% of phagocytic cells in early active MS lesions being proinflammatory microglia.[15]
Lesions
Demyelination in MS: On Klüver-Barrera myelin staining, decoloration in the area of the lesion can be appreciated.
The name multiple sclerosis refers to the scars (sclerae – better known as plaques or lesions) that form in the nervous system. These lesions most commonly affect the white matter in the optic nerve, brain stem, basal ganglia, and spinal cord, or white matter tracts close to the lateral ventricles.[1] The function of white matter cells is to carry signals between grey matter areas, where the processing is done, and the rest of the body. The peripheral nervous system is rarely involved.[8]
MRI machine used as a tool for MS diagnosis
To be specific, MS involves the loss of oligodendrocytes, the cells responsible for creating and maintaining a fatty layer—known as the myelin sheath—which helps the neurons carry electrical signals (action potentials).[1] This results in a thinning or complete loss of myelin, and as the disease advances, the breakdown of the axons of neurons. When the myelin is lost, a neuron can no longer effectively conduct electrical signals.[8] A repair process, called remyelination, takes place in the early phases of the disease, but the oligodendrocytes are unable to completely rebuild the cell's myelin sheath.[92] Repeated attacks lead to successively less effective remyelinations, until a scar-like plaque is built up around the damaged axons.[92] These scars are the origin of the symptoms and during an attack magnetic resonance imaging (MRI) often shows more than 10 new plaques.[1] This could indicate that some number of lesions exist, below which the brain is capable of repairing itself without producing noticeable consequences.[1] Another process involved in the creation of lesions is an abnormal increase in the number of astrocytes due to the destruction of nearby neurons.[1] A number of lesion patterns have been described.[93]
Inflammation
Apart from demyelination, the other sign of the disease is inflammation. Fitting with an immunological explanation, the inflammatory process is caused by T cells, a kind of lymphocytes that plays an important role in the body's defenses.[8] T cells gain entry into the brain as a result of disruptions in the blood–brain barrier. The T cells recognize myelin as foreign and attack it, explaining why these cells are also called "autoreactive lymphocytes".[1]
The attack on myelin starts inflammatory processes, which trigger other immune cells and the release of soluble factors like cytokines and antibodies. A further breakdown of the blood-brain barrier, in turn, causes many other damaging effects, such as swelling, activation of macrophages, and more activation of cytokines and other destructive proteins.[8] Inflammation can potentially reduce transmission of information between neurons in at least three ways.[1] The soluble factors released might stop neurotransmission by intact neurons. These factors could lead to or enhance the loss of myelin, or they may cause the axon to break down completely.[1]
Blood-brain barrier
The blood-brain barrier (BBB) is a part of the capillary system that prevents the entry of T cells into the central nervous system. It may become permeable to these types of cells secondary to an infection by a virus or bacteria. After it repairs itself, typically once the infection has cleared, T cells may remain trapped inside the brain.[8][94]Gadolinium cannot cross a normal BBB, so gadolinium-enhanced MRI is used to show BBB breakdowns.[95]
MS fatigue
The pathophysiology and mechanisms causing MS fatigue are not well understood.[96][97][98] MS fatigue can be affected by body heat,[78][80] and this may differentiate MS fatigue from other primary fatigue.[40][41][84] Fatigability (loss of strength) may increase perception of fatigue, but the two measures warrant independent assessment in clinical studies.[99]
Animation showing dissemination of brain lesions in time and space as demonstrated by monthly MRI studies along a yearMultiple sclerosis as seen on MRI
Multiple sclerosis is typically diagnosed based on the presenting signs and symptoms, in combination with supporting medical imaging and laboratory testing.[5] It can be difficult to confirm, especially early on, since the signs and symptoms may be similar to those of other medical problems.[1][100]
McDonald criteria
The McDonald criteria, which focus on clinical, laboratory, and radiologic evidence of lesions at different times and in different areas, is the most commonly used method of diagnosis[101] with the Schumacher and Poser criteria being of mostly historical significance.[102] The McDonald criteria states that patients with multiple sclerosis should have lesions which are disseminated in time (DIT) and disseminated in space (DIS), i.e. lesions which have appeared in different areas in the brain and at different times.[90] Below is an abbreviated outline of the 2017 McDonald Criteria for diagnosis of MS.
At least 2 clinical attacks with MRI showing 2 or more lesions characteristic of MS.[90]
At least 2 clinical attacks with MRI showing 1 lesion characteristic of MS with clear historical evidence of a previous attack involving a lesion at a distinct location in the CNS.[90]
At least 2 clinical attacks with MRI showing 1 lesion characteristic of MS, with DIT established by an additional clinical attack at a distinct CNS site or by MRI showing an old MS lesion.[90]
1 clinical attack with MRI showing at least 2 lesions characteristic of MS, with DIT established by an additional attack, by MRI showing old MS lesion(s), or presence of oligoclonal bands in CSF.[90]
1 clinical attack with MRI showing 1 lesion characteristic of MS, with DIS established by an additional attack at a different CNS site or by MRI showing old MS lesion(s), and DIT established by an additional attack, by MRI showing old MS lesion(s), or presence of oligoclonal bands in CSF.[90]
As of 2017[update], no single test (including biopsy) can provide a definitive diagnosis.[103]
MRI
Magnetic resonance imaging (MRI) of the brain and spine may show areas of demyelination (lesions or plaques). Gadolinium can be administered intravenously as a contrast agent to highlight active plaques, and by elimination, demonstrate the existence of historical lesions not associated with symptoms at the moment of the evaluation.[104][105]
Central vein signs (CVSs) have been proposed as a good indicator of MS in comparison with other conditions causing white lesions.[106][107][108][109] One small study found fewer CVSs in older and hypertensive people.[110] Further research on CVS as a biomarker for MS is ongoing.[111]
In vivo vs post-portem lesion visibility in MRI scans
Only postmortem MRI allows visualization of sub-millimetric lesions in cortical layers and in the cerebellar cortex.[112]
Cerebrospinal fluid (lumbar puncture)
Testing of cerebrospinal fluid obtained from a lumbar puncture can provide evidence of chronic inflammation in the central nervous system. The cerebrospinal fluid is tested for oligoclonal bands of IgG on electrophoresis, which are inflammation markers found in 75–85% of people with MS.[104][113]
Differential diagnosis
Several diseases present similarly to MS.[114][115] Medical professionals use a patient's specific presentation, history, and exam findings to make an individualized differential. Red flags are findings that suggest an alternate diagnosis, although they do not rule out MS. Red flags include a patient younger than 15 or older than 60, less than 24 hours of symptoms, involvement of multiple cranial nerves, involvement of organs outside of the nervous system, and atypical lab and exam findings.[114][115]
MS progression types. From bottom to top: RRMS, PPMS, SPMS.
Several phenotypes (commonly termed "types"), or patterns of progression, have been described. Phenotypes use the past course of the disease in an attempt to predict the future course. They are important not only for prognosis but also for treatment decisions.
The International Advisory Committee on Clinical Trials of MS describes four types of MS (revised in 2013) in what is known as the Lublin classification:[117][118]
CIS can be characterised as a single lesion seen on MRI which is associated with signs or symptoms found in MS. Due to the McDonald criteria, it does not completely fit the criteria to be diagnosed as MS, hence being named "clinically isolated syndrome". CIS can be seen as the first episode of demyelination in the central nervous system. To be classified as CIS, the attack must last at least 24 hours and be caused by inflammation or demyelination of the central nervous system.[1][119] Patients who suffer from CIS may or may not go on to develop MS, but 30 to 70% of persons who experience CIS will later develop MS.[120]
RRMS is characterized by unpredictable relapses followed by periods of months to years of relative quiet (remission) with no new signs of disease activity. Deficits that occur during attacks may either resolve or leave problems, the latter in about 40% of attacks and being more common the longer a person has had the disease.[1][5] This describes the initial course of 80% of individuals with MS.[1]
PPMS occurs in roughly 10–20% of individuals with the disease, with no remission after the initial symptoms.[5][121] It is characterized by progression of disability from onset, with no, or only occasional and minor, remissions and improvements.[13] The usual age of onset for the primary progressive subtype is later than that of the relapsing-remitting subtype. It is similar to the age that secondary progressive usually begins in RRMS, around 40 years of age.[1]
SPMS occurs in around 65% of those with initial RRMS, who eventually have progressive neurologic decline between acute attacks without any definite periods of remission.[1][13] Occasional relapses and minor remissions may appear.[13] The most common length of time between disease onset and conversion from RRMS to SPMS is 19 years.[122]
Special courses
Independently of the types published by the MS associations, regulatory agencies such as the FDA often consider special courses, trying to reflect some clinical trial results on their approval documents. Some examples could be "highly active MS" (HAMS),[123] "active secondary MS" (similar to the old progressive-relapsing)[124] and "rapidly progressing PPMS".[125]
Also, deficits always resolving between attacks is sometimes referred to as "benign" MS,[126] although people still build up some degree of disability in the long term.[1] On the other hand, the term malignant multiple sclerosis is used to describe people with MS having reached a significant level of disability in a short period.[127]
An international panel has published a standardized definition for the course HAMS.[123]
Although no cure for multiple sclerosis has been found, several therapies have proven helpful. Several effective treatments can decrease the number of attacks and the rate of progression.[24] The primary aims of therapy are returning function after an attack, preventing new attacks, and preventing disability. Starting medications is generally recommended in people after the first attack when more than two lesions are seen on MRI.[130]
The first approved medications used to treat MS were modestly effective, though were poorly tolerated and had many adverse effects.[3] Several treatment options with better safety and tolerability profiles have been introduced,[24] improving the prognosis of MS.
As with any medical treatment, medications used in the management of MS have several adverse effects. Alternative treatments are pursued by some people, despite the shortage of supporting evidence of efficacy.
Initial management of acute flare
During symptomatic attacks, administration of high doses of intravenouscorticosteroids, such as methylprednisolone, is the usual therapy,[1] with oral corticosteroids seeming to have a similar efficacy and safety profile.[131] Although effective in the short term for relieving symptoms, corticosteroid treatments do not appear to have a significant impact on long-term recovery.[132][133] The long-term benefit is unclear in optic neuritis as of 2020.[134][32] The consequences of severe attacks that do not respond to corticosteroids might be treatable by plasmapheresis.[1]
Chronic management
Relapsing-remitting multiple sclerosis
Multiple disease-modifying medications were approved by regulatory agencies for RRMS; they are modestly effective at decreasing the number of attacks.[135]Interferons[136] and glatiramer acetate are first-line treatments[5] and are roughly equivalent, reducing relapses by approximately 30%.[137] Early-initiated long-term therapy is safe and improves outcomes.[138][139]
Treatment of CIS with interferons decreases the chance of progressing to clinical MS.[1][140][141] Efficacy of interferons and glatiramer acetate in children has been estimated to be roughly equivalent to that of adults.[142] The role of some newer agents such as fingolimod,[143]teriflunomide, and dimethyl fumarate,[144] is not yet entirely clear.[145] Making firm conclusions about the best treatment is difficult, especially regarding the long‐term benefit and safety of early treatment, given the lack of studies directly comparing disease-modifying therapies or long-term monitoring of patient outcomes.[146]
The relative effectiveness of different treatments is unclear, as most have only been compared to placebo or a small number of other therapies.[147] Direct comparisons of interferons and glatiramer acetate indicate similar effects or only small differences in effects on relapse rate, disease progression, and MRI measures.[148] There is high confidence that natalizumab, cladribine, or alemtuzumab are decreasing relapses over two years for people with RRMS.[149]Natalizumab and interferon beta-1a (Rebif) may reduce relapses compared to both placebo and interferon beta-1a (Avonex) while Interferon beta-1b (Betaseron), glatiramer acetate, and mitoxantrone may also prevent relapses.[147] Evidence on relative effectiveness in reducing disability progression is unclear.[147] There is moderate confidence that a two-year treatment with natalizumab slows disability progression for people with RRMS.[149] All medications are associated with adverse effects that may influence their risk-to-benefit profiles.[147][149]
Ublituximab was approved for medical use in the United States in December 2022.[150]
In 2011, mitoxantrone was the first medication approved for secondary progressive MS.[152] In this population, tentative evidence supports mitoxantrone moderately slowing the progression of the disease and decreasing rates of relapses over two years.[153][154]
New approved medications continue to emerge. In March 2017, the FDA approved ocrelizumab as a treatment for primary progressive MS in adults, the first drug to gain that approval,[155][156][157] with requirements for several Phase IV clinical trials.[158] It is also used for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.[157] According to a 2021 Cochrane review, ocrelizumab may reduce worsening of symptoms for primary progressive MS and probably increases unwanted effects but makes little or no difference to the number of serious unwanted effects.[159]
In 2019, siponimod and cladribine were approved in the United States for the treatment of secondary progressive multiple sclerosis (SPMS).[155] Subsequently, ozanimod was approved in 2020, and ponesimod was approved in 2021, which were both approved for management of CIS, relapsing MS, and SPMS in the U.S., and RRMS in Europe.[160]
Irritation zone after injection of glatiramer acetate
The disease-modifying treatments have several adverse effects. One of the most common is irritation at the injection site for glatiramer acetate and the interferons (up to 90% with subcutaneous injections and 33% with intramuscular injections).[136][163] Over time, a visible dent at the injection site, due to the local destruction of fat tissue, known as lipoatrophy, may develop.[163] Interferons may produce flu-like symptoms;[164] some people taking glatiramer experience a post-injection reaction with flushing, chest tightness, heart palpitations, and anxiety, which usually lasts less than thirty minutes.[165] More dangerous but much less common are liver damage from interferons,[166]systolic dysfunction (12%), infertility, and acute myeloid leukemia (0.8%) from mitoxantrone,[153][167] and progressive multifocal leukoencephalopathy occurring with natalizumab (occurring in 1 in 600 people treated).[5][168]
Both medications and neurorehabilitation have been shown to improve some symptoms, though neither changes the course of the disease.[171] Some symptoms have a good response to medication, such as bladder spasticity, while others are little changed.[1] Equipment such as catheters for neurogenic bladder dysfunction or mobility aids can help improve functional status.
A multidisciplinary approach is important for improving quality of life; however, it is difficult to specify a 'core team' as many health services may be needed at different points in time.[1] Multidisciplinary rehabilitation programs increase activity and participation of people with MS but do not influence impairment level.[172] Studies investigating information provision in support of patient understanding and participation suggest that while interventions (written information, decision aids, coaching, educational programmes) may increase knowledge, the evidence of an effect on decision making and quality of life is mixed and low certainty.[173] There is limited evidence for the overall efficacy of individual therapeutic disciplines,[174][175] though there is good evidence that specific approaches, such as exercise,[176][177][178][179] and psychological therapies are effective.[180] Cognitive training, alone or combined with other neuropsychological interventions, may show positive effects for memory and attention though firm conclusions are not possible given small sample numbers, variable methodology, interventions and outcome measures.[181] The effectiveness of palliative approaches in addition to standard care is uncertain, due to lack of evidence.[182] The effectiveness of interventions, including exercise, specifically for the prevention of falls in people with MS is uncertain, while there is some evidence of an effect on balance function and mobility.[183]Cognitive behavioral therapy has shown to be moderately effective for reducing MS fatigue.[184] The evidence for the effectiveness of non-pharmacological interventions for chronic pain is insufficient to recommend such interventions alone, however their use in combination with medications may be reasonable.[185]
The spasticity associated with MS can be difficult to manage because of the progressive and fluctuating course of the disease.[187] Although there is no firm conclusion on the efficacy in reducing spasticity, PT interventions can be a safe and beneficial option for patients with multiple sclerosis. Physical therapy including vibration interventions, electrical stimulation, exercise therapy, standing therapy, and radial shock wave therapy (RSWT), were beneficial for limiting spasticity, helping limit excitability, or increasing range of motion.[188]
Alternative treatments
Over 50% of people with MS may use complementary and alternative medicine, although percentages vary depending on how alternative medicine is defined.[189] Regarding the characteristics of users, they are more frequently women, have had MS for a longer time, tend to be more disabled and have lower levels of satisfaction with conventional healthcare.[189] The evidence for the effectiveness for such treatments in most cases is weak or absent.[189][190] Treatments of unproven benefit used by people with MS include dietary supplementation and regimens,[189][191][192]vitamin D,[193]relaxation techniques such as yoga,[189]herbal medicine (including medical cannabis),[189][194][195]hyperbaric oxygen therapy,[196]self-infection with hookworms, reflexology, acupuncture,[189][197] and mindfulness.[198] Evidence suggests vitamin D supplementation, irrespective of the form and dose, provides no benefit for people with MS; this includes for measures such as relapse recurrence, disability, and MRI lesions while effects on health‐related quality of life and fatigue are unclear.[199] There is insufficient evidence supporting high-dose biotin[200][201][202] and some evidence for increased disease activity and higher risk of relapse with its use.[203] A recent review of the effectiveness of Cannabis and Cannabinoids (2022) found that compared with placebo nabiximols probably reduce the severity of spasticity in the short term.[204]
Prognosis
The availability of treatments that modify the course of multiple sclerosis beginning in the 1990s, known as disease-modifying therapies (DMTs), has improved prognosis. These treatments can reduce relapses and slow progression, but there is no cure.[24][205]
The prognosis of MS depends on the subtype of the disease, and there is considerable individual variation in the progression of the disease.[206] In relapsing MS, the most common subtype, a 2016 cohort study found that after a median of 16.8 years from onset, one in ten needed a walking aid, and almost two in ten transitioned to secondary progressive MS, a form characterized by more progressive decline.[24] With treatments available in the 2020s, relapses can be eliminated or substantially reduced. However, "silent progression" of the disease still occurs.[205][207]
In addition to secondary progressive MS (SPMS), a small proportion of people with MS (10–15%) experience progressive decline from the onset, known as primary progressive MS (PPMS). Most treatments have been approved for use in relapsing MS; there are fewer treatments with lower efficacy for progressive forms of MS.[208][205][24] The prognosis for progressive MS is worse, with faster accumulation of disability, though with considerable individual variation.[208] In untreated PPMS, the median time from onset to requiring a walking aid is estimated as seven years.[24] In SPMS, a 2014 cohort study reported that people required a walking aid after an average of five years from the onset of SPMS, and were chair or bed-bound after an average of fifteen years.[209]
After diagnosis of MS, characteristics that predict a worse course are male sex, older age, and greater disability at the time of diagnosis; female sex is associated with a higher relapse rate.[210] Currently, no biomarker can accurately predict disease progression in every patient.[206] Spinal cord lesions, abnormalities on MRI, and more brain atrophy are predictive of a worse course, though brain atrophy as a predictor of disease course is experimental and not used in clinical practice.[210] Early treatment leads to a better prognosis, but a higher relapse frequency when treated with DMTs is associated with a poorer prognosis.[206][210] A 60-year longitudinal population study conducted in Norway found that those with MS had a life expectancy seven years shorter than the general population. Median life expectancy for RRMS patients was 77.8 years and 71.4 years for PPMS, compared to 81.8 years for the general population. Life expectancy for men was five years shorter than for women.[211]
Epidemiology
This section needs to be updated. Please help update this article to reflect recent events or newly available information.(July 2022)
Deaths from multiple sclerosis per million persons in 2012
0
1
2
3–5
6–12
13–25
MS is the most common autoimmune disorder of the central nervous system.[23] The latest estimation of the total number of people with MS was 2.8million globally, with a prevalence of 36 per 100,000 people. Moreover, prevalence varies widely in different regions around the world.[25] In Africa, there are five people per 100,000 diagnosed with MS, compared to South East Asia where the prevalence is nine per 100,000, 112 per 100,000 in the Americas, and 133 per 100,000 in Europe.[212]
Increasing rates of MS may be explained simply by better diagnosis.[2] Studies on populational and geographical patterns have been common[213] and have led to a number of theories about the cause.[17][75][85]
MS usually appears in adults in their late twenties or early thirties but it can rarely start in childhood and after 50 years of age.[2][101] The primary progressive subtype is more common in people in their fifties.[121] Similarly to many autoimmune disorders, the disease is more common in women, and the trend may be increasing.[1][214] As of 2020, globally it is about two times more common in women than in men, and the ratio of women to men with MS is as high as 4:1 in some countries.[215][medical citation needed] In children, it is even more common in females than males,[1] while in people over fifty, it affects males and females almost equally.[121]
Robert Carswell (1793–1857), a British professor of pathology, and Jean Cruveilhier (1791–1873), a French professor of pathologic anatomy, described and illustrated many of the disease's clinical details, but did not identify it as a separate disease.[216] Specifically, Carswell described the injuries he found as "a remarkable lesion of the spinal cord accompanied with atrophy".[1] Under the microscope, Swiss pathologist Georg Eduard Rindfleisch (1836–1908) noted in 1863 that the inflammation-associated lesions were distributed around blood vessels.[217][218]
The French neurologistJean-Martin Charcot (1825–1893) was the first person to recognize multiple sclerosis as a distinct disease in 1868.[216] Summarizing previous reports and adding his own clinical and pathological observations, Charcot called the disease sclerose en plaques.
Diagnosis history
The first attempt to establish a set of diagnostic criteria was also due to Charcot in 1868. He published what now is known as the "Charcot triad", consisting of nystagmus, intention tremor, and telegraphic speech (scanning speech).[219] Charcot also observed cognition changes, describing his patients as having a "marked enfeeblement of the memory" and "conceptions that formed slowly".[26]
The diagnosis was based on Charcot triad and clinical observation until Schumacher made the first attempt to standardize criteria in 1965 by introducing some fundamental requirements: Dissemination of the lesions in time (DIT) and space (DIS), and that "signs and symptoms cannot be explained better by another disease process".[219] The DIT and DIS requirement was later inherited by the Poser and McDonald criteria, whose 2017 revision is in use.[219][206]
During the 20th century, theories about the cause and pathogenesis were developed and effective treatments began to appear in the 1990s.[1] Since the beginning of the 21st century, refinements of the concepts have taken place. The 2010 revision of the McDonald criteria allowed for the diagnosis of MS with only one proved lesion (CIS).[220]
In 1996, the US National Multiple Sclerosis Society (NMSS) (Advisory Committee on Clinical Trials) defined the first version of the clinical phenotypes that is in use. In this first version, they provided standardized definitions for four MS clinical courses: relapsing-remitting (RR), secondary progressive (SP), primary progressive (PP), and progressive relapsing (PR). In 2010, PR was dropped and CIS was incorporated.[220] Three years later, the 2013 revision of the "phenotypes for the disease course" were forced to consider CIS as one of the phenotypes of MS, making obsolete some expressions like "conversion from CIS to MS".[221] Other organizations have proposed later new clinical phenotypes, like HAMS (Highly Active MS).[222]
Historical cases
Photographic study of locomotion of a woman with MS with walking difficulties created in 1887 by Muybridge
There are several historical accounts of people who probably had MS and lived before or shortly after the disease was described by Charcot.
A young woman called Halldora who lived in Iceland around 1200 suddenly lost her vision and mobility but recovered them seven days after. Saint Lidwina of Schiedam (1380–1433), a Dutch nun, may be one of the first clearly identifiable people with MS. From the age of 16 until her death at 53, she had intermittent pain, weakness of the legs and vision loss: symptoms typical of MS.[223] Both cases have led to the proposal of a "Viking gene" hypothesis for the dissemination of the disease.[224]
Augustus Frederick d'Este (1794–1848), son of Prince Augustus Frederick, Duke of Sussex and Lady Augusta Murray and a grandson of George III of the United Kingdom, almost certainly had MS. D'Este left a detailed diary describing his 22 years living with the disease. His diary began in 1822 and ended in 1846, although it remained unknown until 1948. His symptoms began at age 28 with a sudden transient visual loss (amaurosis fugax) after the funeral of a friend. During his disease, he developed weakness in the legs, clumsiness of the hands, numbness, dizziness, bladder disturbance and erectile dysfunction. In 1844, he began to use a wheelchair. Despite his illness, he kept an optimistic view of life.[225][226] Another early account of MS was kept by the British diarist W. N. P. Barbellion, pen name of Bruce Frederick Cummings (1889–1919), who maintained a detailed log of his diagnosis and struggle.[226] His diary was published in 1919 as The Journal of a Disappointed Man.[227]Charles Dickens, a keen observer, described possible bilateral optic neuritis with reduced contrast vision and Uhthoff's phenomenon in the main female character of Bleak House (1852–1853), Esther Summerville.[228]
As of 2022, the pathogenesis of MS, as it relates to Epstein-Barr virus (EBV), is actively investigated, as are disease-modifying therapies; understanding of how risk factors combine with EBV to initiate MS is sought. Whether EBV is the only cause of MS might be better understood if an EBV vaccine is developed and shown to prevent MS as well.[16]
Even though a variety of studies showed the connection between an EBV infection and a later development of multiple sclerosis, the mechanisms behind this correlation are not completely clear, and several theories have been proposed to explain the relationship between the two diseases. It is thought that the involvement of EBV-infected B-cells (B lymphocytes)[229] and the involvement of anti-EBNA antibodies, which appear to be significantly higher in multiple sclerosis patients, play a crucial role in the development of the disease.[230] This is supported by the fact that treatment against B-cells, e.g. ocrelizumab, reduces the symptoms of multiple sclerosis: annual relapses appear less frequently and the disability progression is slower.[231] A 2022 Stanford University study has shown that during an EBV infection, molecular mimicry can occur, where the immune system will produce antibodies against the EBNA1 protein, which at the same time is able to bind to GlialCAM in the myelin. Additionally, they observed a phenomenon which is uncommon in healthy individuals but often detected in multiple sclerosis patients – B-cells are trafficking to the brain and spinal cord, where they are producing oligoclonal antibody bands. A majority of these oligoclonal bands do have an affinity to the viral protein EBNA1, which is cross-reactive to GlialCAM. These antibodies are abundant in approximately 20–25% of multiple sclerosis patients and worsen the autoimmune demyelination which leads consequently to a pathophysiological exacerbation of the disease. Furthermore, the intrathecal oligoclonal expansion with a constant somatic hypermutation is unique in multiple sclerosis when compared to other neuroinflammatory diseases. In the study, there was also the abundance of antibodies with IGHV 3–7 genes measured, which appears to be connected to the disease progress. Antibodies which are IGHV3–7-based are binding with a high affinity to EBNA1 and GlialCAM. This process is actively thriving the demyelination. It is probable that B-cells, expressing IGHV 3–7 genes entered the CSF and underwent affinity maturation after facing GlialCAM, which led consequently to the production of high-affinity anti-GlialCAM antibodies. This was additionally shown in the EAE mouse model where immunization with EBNA1 lead to a strong B-cell response against GlialCAM, which worsened the EAE.[232]
Human endogenous retroviruses
Two members of the human endogenous retroviruses-W (HERV-W) family, namely, ERVWE1 and MS-associated retrovirus (MSRV), may be co-factors in MS immunopathogenesis. HERVs constitute up to 8% of the human genome; most are epigenetically silent, but can be reactivated by exogenous viruses, proinflammatory conditions or oxidative stress.[233][234][235]
Medications
Medications that influence voltage-gated sodium ion channels are under investigation as a potential neuroprotective strategy because of hypothesized role of sodium in the pathological process leading to axonal injury and accumulating disability. There is insufficient evidence of an effect of sodium channel blockers for people with MS.[236]
Pathogenesis
MS is a clinically defined entity with several atypical presentations. Some auto-antibodies have been found in atypical MS cases, giving birth to separate disease families and restricting the previously wider concept of MS.
Anti-AQP4 autoantibodies were found in neuromyelitis optica (NMO), which was previously considered a MS variant. A spectrum of diseases named NMOSD (NMO spectrum diseases) or anti-AQP4 diseases has been accepted.[237] Some cases of MS were presenting anti-MOG autoantibodies, mainly overlapping with the Marburg variant. Anti-MOG autoantibodies were found to be also present in ADEM, and a second spectrum of separated diseases is being considered. This spectrum is named inconsistently across different authors, but it is normally something similar to anti-MOG demyelinating diseases.[237]
A third kind of auto-antibodies is accepted. There are several anti-neurofascin auto-antibodies that damage the Ranvier nodes of the neurons. These antibodies are more related to the peripheral nervous demyelination, but they were also found in chronic progressive PPMS and combined central and peripheral demyelination (CCPD, which is considered another atypical MS presentation).[238]
In addition to the significance of auto-antibodies in MS, four different patterns of demyelination have been reported, opening the door to consider MS as a heterogeneous disease.[239]
MRI brain scan produced using a Gradient-echo phase sequence showing an iron deposit in a white matter lesion (inside green box in the middle of the image; enhanced and marked by red arrow top-left corner)
Since disease progression is the result of degeneration of neurons, the roles of proteins showing loss of nerve tissue such as neurofilaments, tau, and N-acetylaspartate are under investigation.[241][242]
Improvement in neuroimaging techniques such as positron emission tomography (PET) or MRI carry a promise for better diagnosis and prognosis predictions. Regarding MRI, there are several techniques that have already shown some usefulness in research settings and could be introduced into clinical practice, such as double-inversion recovery sequences, magnetization transfer, diffusion tensor, and functional magnetic resonance imaging.[243] These techniques are more specific for the disease than existing ones, but still lack some standardization of acquisition protocols and the creation of normative values.[243] This is particularly the case for proton magnetic resonance spectroscopy, for which a number of methodological variations observed in the literature may underlie continued inconsistencies in central nervous system metabolic abnormalities, particularly in N-acetyl aspartate, myoinositol, choline, glutamate, GABA, and GSH, observed for multiple sclerosis and its subtypes.[244] There are other techniques under development that include contrast agents capable of measuring levels of peripheral macrophages, inflammation, or neuronal dysfunction,[243] and techniques that measure iron deposition that could serve to determine the role of this feature in MS, or that of cerebral perfusion.[243]
COVID-19
The hospitalization rate was found to be higher among individuals with MS and COVID-19 infection, at 10%, while the pooled infection rate is estimated at 4%. The pooled prevalence of death in hospitalized individuals with MS is estimated as 4%.[245]
Metformin
A 2019 study on rats and a 2024 study on mice showed that a first-line medication for the treatment of type 2 diabetes, metformin, could promote remyelination.[246][247] The promising drug is currently being researched on humans in the Octopus trials, a multi-arm, multi-stage trial, focussed on testing existing drugs for other conditions on patients with MS.[248] Currently, clinical trials on humans are ongoing in Belgium, for patients with non-active progressive MS,[249] in the U.K., in combination with clemastine for the treatment of relapsing-remitting MS,[250] and Canada, for MS patients up to 25 years old.[251][252]
Other emerging theories
One emerging hypothesis, referred to as the hygiene hypothesis, suggests that early-life exposure to infectious agents helps to develop the immune system and reduces susceptibility to allergies and autoimmune disorders. The hygiene hypothesis has been linked with MS and microbiome hypotheses.[253]
It has also been proposed that certain bacteria found in the gut use molecular mimicry to infiltrate the brain via the gut–brain axis, initiating an inflammatory response and increasing blood-brain barrier permeability. Vitamin D levels have also been correlated with MS; lower levels of vitamin D correspond to an increased risk of MS, suggesting a reduced prevalence in the tropics – an area with more Vitamin D-rich sunlight – strengthening the impact of geographical location on MS development.[254] MS mechanisms begin when peripheral autoreactive effector CD4+ T cells get activated and move into the CNS. Antigen-presenting cells localize the reactivation of autoreactive effector CD4-T cells once they have entered the CNS, attracting more T cells and macrophages to form the inflammatory lesion.[255][medical citation needed] In MS patients, macrophages and microglia assemble at locations where demyelination and neurodegeneration are actively occurring, and microglial activation is more apparent in the normal-appearing white matter of MS patients.[256]Astrocytes generate neurotoxic chemicals like nitric oxide and TNFα, attract neurotoxic inflammatory monocytes to the CNS, and are responsible for astrogliosis, the scarring that prevents the spread of neuroinflammation and kills neurons inside the scarred area.[257][bettersourceneeded]
In 2024, scientists shared research on their findings of ancient migration to northern Europe from the Yamnaya area of culture,[258] tracing MS-risk gene variants dating back around 5,000 years.[259][260] The MS-risk gene variants protected ancient cattle herders from animal diseases,[261] but modern lifestyles, diets and better hygiene, have allowed the gene to develop, resulting in the higher risk of MS today.[262]
Interferon beta-1a is a cytokine in the interferon family used to treat multiple sclerosis (MS). It is produced by mammalian cells, while interferon beta-1b is produced in modified E. coli. Some research indicates that interferon injections may result in an 18–38% reduction in the rate of MS relapses.
Peripheral neuropathy, often shortened to neuropathy, refers to damage or disease affecting the nerves. Damage to nerves may impair sensation, movement, gland function, and/or organ function depending on which nerve fibers are affected. Neuropathies affecting motor, sensory, or autonomic nerve fibers result in different symptoms. More than one type of fiber may be affected simultaneously. Peripheral neuropathy may be acute or chronic, and may be reversible or permanent.
Neuromyelitis optica spectrum disorders (NMOSD) are a spectrum of autoimmune diseases characterized by acute inflammation of the optic nerve and the spinal cord (myelitis). Episodes of ON and myelitis can be simultaneous or successive. A relapsing disease course is common, especially in untreated patients.
Natalizumab, sold under the brand name Tysabri among others, is a medication used to treat multiple sclerosis and Crohn's disease. It is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin. It is given by intravenous infusion. The drug is believed to work by reducing the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood–brain barrier.
Interferon beta-1b is a cytokine in the interferon family used to treat the relapsing-remitting and secondary-progressive forms of multiple sclerosis (MS). It is approved for use after the first MS event. Closely related is interferon beta 1a, also indicated for MS, with a very similar drug profile.
Cladribine, sold under the brand name Leustatin, among others, is a medication used to treat hairy cell leukemia and B-cell chronic lymphocytic leukemia. Cladribine, sold under the brand name Mavenclad, is used for the treatment of adults with highly active forms of relapsing-remitting multiple sclerosis.
Experimental autoimmune encephalomyelitis, sometimes experimental allergic encephalomyelitis (EAE), is an animal model of brain inflammation. It is an inflammatory demyelinating disease of the central nervous system (CNS). It is mostly used with rodents and is widely studied as an animal model of the human CNS demyelinating diseases, including multiple sclerosis (MS) and acute disseminated encephalomyelitis (ADEM). EAE is also the prototype for T-cell-mediated autoimmune disease in general.
Multiple sclerosis is an inflammatory demyelinating disease of the CNS in which activated immune cells invade the central nervous system and cause inflammation, neurodegeneration, and tissue damage. The underlying cause is currently unknown. Current research in neuropathology, neuroimmunology, neurobiology, and neuroimaging, together with clinical neurology, provide support for the notion that MS is not a single disease but rather a spectrum.
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS). Several therapies for it exist, although there is no known cure.
Inflammatory demyelinating diseases (IDDs), sometimes called Idiopathic (IIDDs) due to the unknown etiology of some of them, are a heterogenous group of demyelinating diseases - conditions that cause damage to myelin, the protective sheath of nerve fibers - that occur against the background of an acute or chronic inflammatory process. IDDs share characteristics with and are often grouped together under Multiple Sclerosis. They are sometimes considered different diseases from Multiple Sclerosis, but considered by others to form a spectrum differing only in terms of chronicity, severity, and clinical course.
The signs and symptoms of multiple sclerosis (MS) encompass a wide range of neurological and physical manifestations, including vision problems, muscle weakness, coordination difficulties, and cognitive impairment, varying significantly in severity and progression among individuals.
Research in multiple sclerosis may find new pathways to interact with the disease, improve function, curtail attacks, or limit the progression of the underlying disease. Many treatments already in clinical trials involve drugs that are used in other diseases or medications that have not been designed specifically for multiple sclerosis. There are also trials involving the combination of drugs that are already in use for multiple sclerosis. Finally, there are also many basic investigations that try to understand the disease better and in the future may help to find new treatments.
Tumefactive multiple sclerosis is a condition in which the central nervous system of a person has multiple demyelinating lesions with atypical characteristics for those of standard multiple sclerosis (MS). It is called tumefactive as the lesions are "tumor-like" and they mimic tumors clinically, radiologically and sometimes pathologically.
Paolo Zamboni is an Italian doctor and scientist. He is full Professor and Director of the School of Vascular Surgery at the University of Ferrara in Italy.
Current standards for diagnosing multiple sclerosis (MS) are based on the 2018 revision of McDonald criteria. They rely on MRI detection of demyelinating lesions in the CNS, which are distributed in space (DIS) and in time (DIT). It is also a requirement that any possible known disease that produces demyelinating lesions is ruled out before applying McDonald's criteria.
Multiple sclerosis (MS) can be pathologically defined as the presence of distributed glial scars (scleroses) in the central nervous system that must show dissemination in time (DIT) and in space (DIS) to be considered MS lesions.
There are several ways for pharmaceuticals for treating multiple sclerosis (MS) to reach the market.
Rhonda Renee Voskuhl is an American physician, research scientist, and professor. She is a member of the Brain Research Institute (BRI) at the David Geffen School of Medicine at UCLA and is the director of its Multiple Sclerosis Program. Voskuhl has published numerous scientific articles in academic journals and has served in the role of principal investigator for several treatment trials investigating potential treatments for multiple sclerosis (MS).
Radiologically isolated syndrome (RIS) is a clinical situation in which a person has white matter lesions suggestive of multiple sclerosis (MS), as shown on an MRI scan that was done for reasons unrelated to MS symptoms. The nerve lesions in these people show dissemination in space with an otherwise normal neurological examination and without historical accounts of typical MS symptoms.
Several biomarkers for diagnosis of multiple sclerosis, disease evolution and response to medication are under research. While most of them are still under research, there are some of them already well stablished:
1 2 Nakahara J, Maeda M, Aiso S, Suzuki N (February 2012). "Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy". Clinical Reviews in Allergy & Immunology. 42 (1): 26–34. doi:10.1007/s12016-011-8287-6. PMID22189514. S2CID21058811.
1 2 3 4 5 6 7 Tsang BK, Macdonell R (December 2011). "Multiple sclerosis- diagnosis, management and prognosis". Australian Family Physician. 40 (12): 948–955. PMID22146321.
↑ Liu Z, Liao Q, Wen H, Zhang Y (June 2021). "Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis". Autoimmunity Reviews. 20 (6): 102826. doi:10.1016/j.autrev.2021.102826. PMID33878488. S2CID233325057.
1 2 3 Alphonsus KB, Su Y, D'Arcy C (April 2019). "The effect of exercise, yoga and physiotherapy on the quality of life of people with multiple sclerosis: Systematic review and meta-analysis". Complementary Therapies in Medicine. 43: 188–195. doi:10.1016/j.ctim.2019.02.010. PMID30935529. S2CID86669723.
↑ Murray ED, Buttner EA, Price BH (2012). "Depression and Psychosis in Neurological Practice". In Daroff R, Fenichel G, Jankovic J, Mazziotta J (eds.). Bradley's neurology in clinical practice (6thed.). Philadelphia, PA: Elsevier/Saunders. ISBN978-1-4377-0434-1.
1 2 3 Piryonesi SM, Rostampour S, Piryonesi SA (April 2021). "Predicting falls and injuries in people with multiple sclerosis using machine learning algorithms". Multiple Sclerosis and Related Disorders. 49: 102740. doi:10.1016/j.msard.2021.102740. PMID33450500. S2CID231624230.
1 2 3 Clanet M (June 2008). "Jean-Martin Charcot. 1825 to 1893". International MS Journal. 15 (2): 59–61. PMID18782501. * Charcot J (1868). "Histologie de la sclerose en plaques". Gazette des Hopitaux, Paris. 41: 554–5.
↑ "Fatigue". Letchworth Garden City, United Kingdom: Multiple Sclerosis Trust.
↑ Moore H, Nair KP, Baster K, Middleton R, Paling D, Sharrack B (August 2022). "Fatigue in multiple sclerosis: A UK MS-register based study". Multiple Sclerosis and Related Disorders. 64: 103954. doi:10.1016/j.msard.2022.103954. PMID35716477.
1 2 Tataru N, Vidal C, Decavel P, Berger E, Rumbach L (2006). "Limited impact of the summer heat wave in France (2003) on hospital admissions and relapses for multiple sclerosis". Neuroepidemiology. 27 (1): 28–32. doi:10.1159/000094233. PMID16804331. S2CID20870484.
↑ Heesen C, Mohr DC, Huitinga I, Bergh FT, Gaab J, Otte C, etal. (March 2007). "Stress regulation in multiple sclerosis: current issues and concepts". Multiple Sclerosis. 13 (2): 143–148. doi:10.1177/1352458506070772. PMID17439878. S2CID8262595.
↑ Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Brex PA (April 2019). "UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines". Practical Neurology. 19 (2): 106–114. doi:10.1136/practneurol-2018-002060. PMID30612100.
↑ Hassan-Smith G, Douglas MR (October 2011). "Epidemiology and diagnosis of multiple sclerosis". British Journal of Hospital Medicine. 72 (10): M146-51. doi:10.12968/hmed.2011.72.Sup10.M146. PMID22041658.
↑ Simpson S, Wang W, Otahal P, Blizzard L, van der Mei IA, Taylor BV (November 2019). "Latitude continues to be significantly associated with the prevalence of multiple sclerosis: an updated meta-analysis". Journal of Neurology, Neurosurgery, and Psychiatry. 90 (11): 1193–1200. doi:10.1136/jnnp-2018-320189. PMID31217172.
1 2 Davis SL, Jay O, Wilson TE (2018). "Thermoregulatory dysfunction in multiple sclerosis". In Romanovsky AA (ed.). Thermoregulation: From Basic Neuroscience to Clinical Neurology, Part II. Handbook of Clinical Neurology. Vol.157. pp.701–714. doi:10.1016/B978-0-444-64074-1.00042-2. ISBN978-0-444-64074-1. PMID30459034.
↑ Leavitt VM, De Meo E, Riccitelli G, Rocca MA, Comi G, Filippi M, etal. (November 2015). "Elevated body temperature is linked to fatigue in an Italian sample of relapsing-remitting multiple sclerosis patients". Journal of Neurology. 262 (11): 2440–2442. doi:10.1007/s00415-015-7863-8. PMID26223805.
1 2 Christogianni A, O'Garro J, Bibb R, Filtness A, Filingeri D (November 2022). "Heat and cold sensitivity in multiple sclerosis: A patient-centred perspective on triggers, symptoms, and thermal resilience practices". Multiple Sclerosis and Related Disorders. 67: 104075. doi:10.1016/j.msard.2022.104075. PMID35963205.
↑ Spitsin S, Koprowski H (2008). "Role of Uric Acid in Multiple Sclerosis". In Rodriguez M (ed.). Advances in multiple Sclerosis and Experimental Demyelinating Diseases. Current Topics in Microbiology and Immunology. Vol.318. pp.325–342. doi:10.1007/978-3-540-73677-6_13. ISBN978-3-540-73676-9. PMID18219824.
↑ Trojano M, Paolicelli D (November 2001). "The differential diagnosis of multiple sclerosis: classification and clinical features of relapsing and progressive neurological syndromes". Neurological Sciences. 22 (Suppl 2): S98-102. doi:10.1007/s100720100044. PMID11794488. S2CID3057096.
1 2 World Health Organization (2008). Atlas: Multiple Sclerosis Resources in the World 2008. Geneva: World Health Organization. pp.15–16. hdl:10665/43968. ISBN978-92-4-156375-8.
↑ Link H, Huang YM (November 2006). "Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness". Journal of Neuroimmunology. 180 (1–2): 17–28. doi:10.1016/j.jneuroim.2006.07.006. PMID16945427. S2CID22724352.
1 2 3 Hauser SL (2022). "Chapter 442: Diseases of the Spinal Cord". In Loscalzo J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL (eds.). Harrison's principles of internal medicine (21sted.). New York: McGraw-Hill. p.3466. ISBN978-1-264-26849-8. OCLC1282172709.
↑ Saida T (November 2004). "多発性硬化症：再燃時の治療と再発予防" [Multiple sclerosis: treatment and prevention of relapses and progression in multiple sclerosis]. 臨床神経学[Rinsho Shinkeigaku] (Review) (in Japanese). 44 (11): 796–8. PMID15651294.
↑ Pittock SJ, Rodriguez M (2008). "Benign Multiple Sclerosis: A Distinct Clinical Entity with Therapeutic Implications". In Rodriguez M (ed.). Advances in multiple Sclerosis and Experimental Demyelinating Diseases. Current Topics in Microbiology and Immunology. Vol.318. pp.1–17. doi:10.1007/978-3-540-73677-6_1. ISBN978-3-540-73676-9. PMID18219812.
↑ Stadelmann C, Brück W (November 2004). "Lessons from the neuropathology of atypical forms of multiple sclerosis". Neurological Sciences. 25 (Suppl 4): S319–S322. doi:10.1007/s10072-004-0333-1. PMID15727225. S2CID21212935.
↑ Burton JM, O'Connor PW, Hohol M, Beyene J (December 2012). "Oral versus intravenous steroids for treatment of relapses in multiple sclerosis". The Cochrane Database of Systematic Reviews. 12: CD006921. doi:10.1002/14651858.CD006921.pub3. PMID23235634.
↑ Hassan-Smith G, Douglas MR (November 2011). "Management and prognosis of multiple sclerosis". British Journal of Hospital Medicine. 72 (11): M174-6. doi:10.12968/hmed.2011.72.Sup11.M174. PMID22082979.
↑ Qizilbash N, Mendez I, Sanchez-de la Rosa R (January 2012). "Benefit-risk analysis of glatiramer acetate for relapsing-remitting and clinically isolated syndrome multiple sclerosis". Clinical Therapeutics. 34 (1): 159–176.e5. doi:10.1016/j.clinthera.2011.12.006. PMID22284996.
↑ Bates D (January 2011). "Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials". Neurology. 76 (1 Suppl 1): S14-25. doi:10.1212/WNL.0b013e3182050388. PMID21205678. S2CID362182.
↑ Clerico M, Faggiano F, Palace J, etal. (April 2008). "Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis". Cochrane Database Syst Rev (2): CD005278. doi:10.1002/14651858.CD005278.pub3. PMID18425915.
↑ "MS Decisions aid". Letchworth Garden City, United Kingdom: Multiple Sclerosis Trust. 3 December 2023. Retrieved 3 December 2023.
↑ Keegan BM (22 December 2011). "Multiple Sclerosis". In Bope ET, Kellerman RD (eds.). Conn's Current Therapy 2012: Expert Consult – Online and Print. Elsevier Health Sciences. p.626. ISBN978-1-4557-0738-6.
↑ Penner IK, Schreiber H (2023). "Disease Modifying Immunotherapies and Fatigue". In Penner IK (ed.). Fatigue in Multiple Sclerosis. Springer, Cham. pp.161–177. ISBN978-3-031-13498-2.
1 2 Balak DM, Hengstman GJ, Çakmak A, Thio HB (December 2012). "Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review". Multiple Sclerosis. 18 (12): 1705–17. doi:10.1177/1352458512438239. hdl:1765/73097. PMID22371220.
↑ Sládková T, Kostolanský F (2006). "The role of cytokines in the immune response to influenza A virus infection". Acta Virologica. 50 (3): 151–62. PMID17131933.
↑ La Mantia L, Munari LM, Lovati R (May 2010). "Glatiramer acetate for multiple sclerosis". The Cochrane Database of Systematic Reviews (5): CD004678. doi:10.1002/14651858.CD004678.pub2. PMID20464733.
↑ Tremlett H, Oger J (November 2004). "Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis". Journal of Neurology. 251 (11): 1297–303. doi:10.1007/s00415-004-0619-5. PMID15592724. S2CID12529733.
↑ "NDA 204063 – FDA Approved Labeling Text"(PDF). US Food and Drug Agency. 27 March 2013. Archived(PDF) from the original on 4 October 2013. Retrieved 5 April 2013. "NDA Approval"(PDF). US Food and Drug Agency. 27 March 2013. Archived(PDF) from the original on 4 October 2013. Retrieved 5 April 2013.
↑ Gallien P, Nicolas B, Robineau S, Pétrilli S, Houedakor J, Durufle A (July 2007). "Physical training and multiple sclerosis". Annales de Réadaptation et de Médecine Physique. 50 (6): 373–6, 369–72. doi:10.1016/j.annrmp.2007.04.004. PMID17482708.
↑ van den Akker LE, Beckerman H, Collette EH, Eijssen IC, Dekker J, de Groot V (November 2016). "Effectiveness of cognitive behavioral therapy for the treatment of fatigue in patients with multiple sclerosis: A systematic review and meta-analysis". Journal of Psychosomatic Research. 90: 33–42. doi:10.1016/j.jpsychores.2016.09.002. PMID27772557.
↑ Corvillo I, Varela E, Armijo F, Alvarez-Badillo A, Armijo O, Maraver F (December 2017). "Efficacy of aquatic therapy for multiple sclerosis: a systematic review". Eur J Phys Rehabil Med (Review). 53 (6): 944–952. doi:10.23736/S1973-9087.17.04570-1. PMID28215060.
↑ Etoom M, Khraiwesh Y, Lena F, etal. (November 2018). "Effectiveness of Physiotherapy Interventions on Spasticity in People With Multiple Sclerosis: A Systematic Review and Meta-Analysis". Am J Phys Med Rehabil. 97 (11): 793–807. doi:10.1097/PHM.0000000000000970. PMID29794531. S2CID44156766.
1 2 3 4 5 6 7 Huntley A (January 2006). "A review of the evidence for efficacy of complementary and alternative medicines in MS". International MS Journal. 13 (1): 5–12, 4. PMID16420779.
↑ Olsen SA (2009). "A review of complementary and alternative medicine (CAM) by people with multiple sclerosis". Occupational Therapy International. 16 (1): 57–70. doi:10.1002/oti.266. PMID19222053.
↑ Inojosa H, Proschmann U, Akgün K, Ziemssen T (April 2021). "A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition". J Neurol. 268 (4): 1210–1221. doi:10.1007/s00415-019-09489-5. PMID31363847. S2CID198999832. Expanded Disability Status Scale (EDSS) 6.0 is equivalent to requiring a walking aid, and EDSS 8.0 equivalent to chair or bedbound
↑ Minagar A, Shapshak P, Alexander JS (28 December 2004). "Pathogenesis of HIV-Associated Dementia and Multiple Sclerosis: Role of Microglia and Astrocytes". In Aschner M, Costa LG (eds.). The Role of Glia in Neurotoxicity (2nded.). CRC Press. pp.283–298. doi:10.1201/9781420039740-21. ISBN978-0-429-12860-8.
↑ Barrie W, Yang Y, Irving-Pease E, Attfield KE, Scorrano G, Jensen LT, etal. (6 October 2023). "Elevated genetic risk for multiple sclerosis originated in Steppe Pastoralist populations". bioRxiv10.1101/2023.10.06.561165. Our findings also support the interpretation of increased pathogen pressure as a driver of positive selection on immunogenetic variants associated with risk of the autoimmune disease multiple sclerosis in Steppe populations around 5,000 years ago[59]
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
